On Friday, Shares of ABIOMED, Inc. (NASDAQ:ABMD), gained 1.44% to $95.68.
Abiomed, declared that the Company will webcast presentations at its Investor Day held in Boston, MA on Tuesday, August 11, 2015, from 9:00 a.m. to about 12:00 p.m. EDT.
Abiomed will host a physician panel of experts, present our corporate strategy and 5-year revenue projection, describe a new patient population of interest and unveil a future product for heart failure.
ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
At the end of Friday’s trade, Shares of Sonic Corporation (NASDAQ:SONC), gained 0.51% to $29.41.
Sonic Corp., declared that its Board of Directors has authorized a stock repurchase program for up to $145 million of its common stock through August 31, 2016. Share repurchases may be made from time to time in the open market or otherwise, counting through an accelerated share repurchase program, under the terms of a Rule 10b5-1 plan, in privately negotiated transactions or in round lot or block transactions.
The Company also declared that its Board of Directors has approved the continuation of the Company’s quarterly cash dividend program. Starting in the first fiscal quarter of 2016, the Company anticipates to declare a quarterly dividend of $0.11 per share of common stock, which represents an enhance of 22% from the current quarterly dividend of $0.09 per share.
Sonic Corp. operates and franchises a chain of quick-service drive-in restaurants in the United States. As of March 13, 2015, the company operated 3,517 restaurants in 44 states. It also leases signs and real estate. The company was founded in 1953 and is headquartered in Oklahoma City, Oklahoma.
Finally, Supernus Pharmaceuticals Inc (NASDAQ:SUPN), ended its last trade with -5.07% gain, and closed at $17.60.
Supernus Pharmaceuticals, stated financial results for the second quarter of 2015 and associated company developments.
Commercial Update
Second quarter 2015 product prescriptions for Trokendi XR(R) and Oxtellar XR(R) grew by 12,561, or 16%, over the first quarter of 2015, an acceleration in growth as contrast to 8,024, or 11%, between the first quarter of 2015 and the fourth quarter of 2014. Second quarter 2015 product prescriptions grew by 99% as compared to second quarter 2014.
“Strong growth in product prescriptions in the quarter reflects the solid underlying fundamentals of our epilepsy portfolio and an acceleration of sequential quarterly prescription growth contrast to the previous quarter,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
